{"id":"895f08c4-cad7-582f-bee8-50d0f0d513a4","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-nr-obese-men","predicate":"does_not_improve_in_tested_population","statement":"Twelve weeks of NR did not improve clamp insulin sensitivity, glucose production or disposal, lipid mobilization, resting energy expenditure or body composition in this trial.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"14d9701b-4817-5785-96fc-0e45cd0e8da5","mechanism_event_label":"NR did not produce a general metabolic improvement in these insulin-resistant men.","subject":{"id":"7bb72d0e-e20d-51bc-b88b-7ff29dc2ad4a","slug":"nicotinamide-riboside","display_name":"Nicotinamide riboside","entity_type_key":"small_molecule"},"object":{"id":"f61e2e6e-d803-54f6-ab62-4ffa080c9ad6","slug":"insulin-stimulated-glucose-uptake","display_name":"Insulin-stimulated glucose uptake","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"14d9701b-4817-5785-96fc-0e45cd0e8da5","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-nr-obese-men-event","event_type":"observed_intervention","label":"NR did not produce a general metabolic improvement in these insulin-resistant men.","description":"Twelve weeks of NR did not improve clamp insulin sensitivity, glucose production or disposal, lipid mobilization, resting energy expenditure or body composition in this trial.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"7bb72d0e-e20d-51bc-b88b-7ff29dc2ad4a","slug":"nicotinamide-riboside","display_name":"Nicotinamide riboside","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f61e2e6e-d803-54f6-ab62-4ffa080c9ad6","slug":"insulin-stimulated-glucose-uptake","display_name":"Insulin-stimulated glucose uptake","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"Niacin precursor form and the measured endpoint are separate graph entities.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-clinical-sources/dollerup2018.abstract.txt\", \"locator\": \"Indexed primary abstract\", \"file_sha256\": \"dd5668627aa4f11bce6460dd6d163248c711dd43b85b6265a4055cf96012b241\", \"start_char\": 0, \"end_char\": 1987, \"text_sha256\": \"dd5668627aa4f11bce6460dd6d163248c711dd43b85b6265a4055cf96012b241\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind trial; 40 sedentary obese insulin-resistant men aged 40–70","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"NR 1,000 mg twice daily versus placebo for 12 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Different precursor and population from the NMN female trial. No efficacy demonstrated for the tested endpoints; short tolerability observations do not establish universal long-term safety.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"NR did not produce a general metabolic improvement in these insulin-resistant men.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[nia-clin-dollerup2018] A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. (2018). https://pubmed.ncbi.nlm.nih.gov/29992272/ DOI: 10.1093/ajcn/nqy132","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Clamp glucose metabolism and body composition","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"f7705c55-3881-5dcf-90a4-7b9d929a569a","evidence_kind":"source_excerpt","locator":"Lines 1543-1555","start_line":1543,"end_line":1555,"excerpt":"### nia-clin-nr-obese-men\nTwelve weeks of NR did not improve clamp insulin sensitivity, glucose production or disposal, lipid mobilization, resting energy expenditure or body composition in this trial.\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: NR did not produce a general metabolic improvement in these insulin-resistant men.\norganism: Homo sapiens\ntissue_or_cell_type: Clamp glucose metabolism and body composition\nexperimental_model: Randomized double-blind trial; 40 sedentary obese insulin-resistant men aged 40–70\nlimitations: Different precursor and population from the NMN female trial. No efficacy demonstrated for the tested endpoints; short tolerability observations do not establish universal long-term safety.\nexposure: NR 1,000 mg twice daily versus placebo for 12 weeks\ncross_nutrient: Niacin precursor form and the measured endpoint are separate graph entities.\nevidence_span: {\"source_cache\": \"artifacts/niacin-clinical-sources/dollerup2018.abstract.txt\", \"locator\": \"Indexed primary abstract\", \"file_sha256\": \"dd5668627aa4f11bce6460dd6d163248c711dd43b85b6265a4055cf96012b241\", \"start_char\": 0, \"end_char\": 1987, \"text_sha256\": \"dd5668627aa4f11bce6460dd6d163248c711dd43b85b6265a4055cf96012b241\"}\n[nia-clin-dollerup2018] A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. (2018). https://pubmed.ncbi.nlm.nih.gov/29992272/ DOI: 10.1093/ajcn/nqy132","model_system":"Randomized double-blind trial; 40 sedentary obese insulin-resistant men aged 40–70","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [nia-clin-dollerup2018] A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. (2018). https://pubmed.ncbi.nlm.nih.gov/29992272/ DOI: 10.1093/ajcn/nqy132","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}